- Home
- GLRE vs PBYI Comparison
GLRE vs PBYI Comparison
Compare GLRE & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | PBYI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 467.2M |
| IPO Year | 2007 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GLRE | PBYI |
|---|---|---|
| Price | $15.11 | $11.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.2K | ★ 322.5K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | 0.08 |
| Revenue | ★ $729,777,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | ★ $85.06 | $140.75 |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $4.58 |
| 52 Week High | $19.39 | $11.38 |
Technical Indicators
Market Signals| Indicator | GLRE | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 63.64 |
| Support Level | $14.53 | $9.04 |
| Resistance Level | $15.48 | N/A |
| Average True Range (ATR) | 0.37 | 0.48 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 59.12 | 76.56 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.